Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of inclisiran in subjects with elevated LDL-C
NCT02314442Phase 1Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- May 2015
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of inclisiran in hypercholesterolemia (4 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Proportion of subjects experiencing adverse events at 180 days. Started Dec 2014; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02314442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314442.